Business Description
Sumitomo Pharma Co Ltd
ISIN : JP3495000006
Total Employee Number:
3,832Description
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.23 | |||||
Equity-to-Asset | 0.36 | |||||
Debt-to-Equity | 0.74 | |||||
Debt-to-EBITDA | 1.97 | |||||
Interest Coverage | 10.31 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 1.98 | |||||
Beneish M-Score | -1.5 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -6.6 | |||||
3-Year Book Growth Rate | -10.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -13.84 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.08 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 1.18 | |||||
9-Day RSI | 6.59 | |||||
14-Day RSI | 14.41 | |||||
3-1 Month Momentum % | -21.58 | |||||
6-1 Month Momentum % | -34.47 | |||||
12-1 Month Momentum % | 29.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.03 | |||||
Quick Ratio | 0.71 | |||||
Cash Ratio | 0.18 | |||||
Days Inventory | 161.47 | |||||
Days Sales Outstanding | 88.08 | |||||
Days Payable | 78.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | 17.83 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 56.67 | |||||
Operating Margin % | 23.18 | |||||
Net Margin % | 23.58 | |||||
EBITDA Margin % | 24.39 | |||||
FCF Margin % | 13.85 | |||||
OCF Margin % | 15.47 | |||||
ROE % | 44.8 | |||||
ROA % | 13.79 | |||||
ROIC % | 15.04 | |||||
3-Year ROIIC % | -58.65 | |||||
ROC (Joel Greenblatt) % | 167.88 | |||||
ROCE % | 20.32 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 4.78 | |||||
Forward PE Ratio | 6.4 | |||||
PE Ratio without NRI | 4.78 | |||||
Shiller PE Ratio | 117.4 | |||||
Price-to-Owner-Earnings | 5.41 | |||||
PS Ratio | 1.13 | |||||
PB Ratio | 1.74 | |||||
Price-to-Free-Cash-Flow | 7.92 | |||||
Price-to-Operating-Cash-Flow | 7.12 | |||||
EV-to-EBIT | 6.73 | |||||
EV-to-Forward-EBIT | 13.11 | |||||
EV-to-EBITDA | 6.73 | |||||
EV-to-Forward-EBITDA | 16.76 | |||||
EV-to-Revenue | 1.64 | |||||
EV-to-Forward-Revenue | 1.25 | |||||
EV-to-FCF | 11.55 | |||||
Price-to-GF-Value | 1.53 | |||||
Price-to-Projected-FCF | 3.01 | |||||
Price-to-Median-PS-Value | 0.81 | |||||
Earnings Yield (Greenblatt) % | 14.86 | |||||
FCF Yield % | 11.18 | |||||
Forward Rate of Return (Yacktman) % | 6.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:DNPUF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sumitomo Pharma Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,991.918 | ||
| EPS (TTM) ($) | 1.816 | ||
| Beta | 0.3535 | ||
| 3-Year Sharpe Ratio | 0.59 | ||
| 3-Year Sortino Ratio | 1.55 | ||
| Volatility % | 85.4 | ||
| 14-Day RSI | 14.41 | ||
| 14-Day ATR ($) | 0.066076 | ||
| 20-Day SMA ($) | 8.95775 | ||
| 12-1 Month Momentum % | 29.97 | ||
| 52-Week Range ($) | 7.24 - 19.2 | ||
| Shares Outstanding (Mil) | 448.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sumitomo Pharma Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sumitomo Pharma Co Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sumitomo Pharma Co Ltd Frequently Asked Questions
What is Sumitomo Pharma Co Ltd(DNPUF)'s stock price today?
The current price of DNPUF is $8.40. The 52 week high of DNPUF is $19.20 and 52 week low is $7.24.
When is next earnings date of Sumitomo Pharma Co Ltd(DNPUF)?
The next earnings date of Sumitomo Pharma Co Ltd(DNPUF) is .
Does Sumitomo Pharma Co Ltd(DNPUF) pay dividends? If so, how much?
Sumitomo Pharma Co Ltd(DNPUF) does not pay dividend.
Guru Commentaries on OTCPK:DNPUF
No articles.
Press Release
Articles on Sumitomo Pharma Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers